Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

NCT05372016 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

HPV Infections
Cervical Cancer
Vulvar Cancer
Vaginal Cancer
CIN1
CIN2
CIN3
VaIN1
VaIN2
VaIN3
Genital Wart
VIN 1
VIN 2
VIN 3
AIS

Interventions

BIOLOGICAL: Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
BIOLOGICAL: Active Comparator: GARDASIL ®9

Sponsor

Shanghai Bovax Biotechnology Co., Ltd.

Collaborators

[object Object]